IFN-γ treatment protocol for MHC-I^lo/PD-L1⁺ pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential.

ABSTRACT:

Background

Many cancer cells express a major histocompatibility complex class I low/ programmed cell death 1 ligand 1 positive (MHC-I^lo/PD-L1⁺) cell surface profile. For immunotherapy, there is, thus, an urgent need to restore presentation competence of cancer cells with defects in MHC-I processing/presentation combined with immune interventions that tackle the tumor-initiated PD-L1/PD-1 signaling axis. Using pancreatic ductal adenocarcinoma cells (PDACCs) as a model, we here explored if (and how) expression/processing of tumor antigens via transporters associated with antigen processing (TAP) affects priming of CD8 T cells in PD-1/PD-L1-competent/-deficient mice.

Methods

We generated tumor antigen-expressing vectors, immunized TAP-competent/-deficient

SUBMITTER: Stifter K 

PROVIDER: S-EPMC7462314 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature